Andreas Tiede/ResearchGate
Dec 8, 2025, 11:08
Andreas Tiede: This Will Change Hematology Forever
Andreas Tiede, Professor, Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, shared on LinkedIn:
”This will change Hematology forever: the milder Aza/Ven combination is more effective and less harmful than the traditional 3+7 chemo regimen in fit AML patients.
Groundbreaking data at ASH2025”
The American Society of Hematology Congress 2025 (ASH25) is officially underway in Orlando, Florida, from December 6 to 9.
It aims to bring together hematology professionals from across the globe.
Throughout the meeting, experts will present new research, clinical breakthroughs, and innovations that are defining the future of hematologic care.
More from ASH25 featured in Hemostasis Today.
-
Sep 10, 2026, 05:12Douglas S. Campbell: Great to See a Strong Japanese Presence in 2026 Lasker Awards
-
Sep 10, 2026, 05:11Jan Hartmann: New Transformative Treatment for Hemophilia A
-
Sep 10, 2026, 05:09Shelby Bradford: Award-Winning Science Incoming
-
Sep 9, 2026, 17:57CRISPR/Cas Gene Editing in β-Thalassemia: From Molecular Correction to Clinical Reality
-
Sep 9, 2026, 17:38Cardiovascular Health in Bleeding Disorders – EHC
-
Sep 9, 2026, 17:33Manasvi Shah: Co-Inheritance of Alpha Globin Gene Multiplication With Beta Globin Gene Abnormalities
-
Sep 9, 2026, 17:29Christina Crossette-Thambiah: One of the Largest Studies to Date in Antiphospholipid Syndrome
-
Sep 9, 2026, 17:25Alan Nurden: A miR-146a Variant Reveals a New Pathway Linking Platelet Metabolism and Thrombosis
-
Sep 9, 2026, 17:17When Is Thrombophilia Testing Appropriate and How Can the Evidence Guide Clinical Care? – ISTH